On Tuesday, the company announced a $100 million Series C round. Katz chalks up the size of this round to growth in revenue over the past year – the company is reporting about a 250% increase in annual recurring revenue. The company has about 100 clients, says Katz, including top pharma companies like Novartis and AstraZeneca. Pauline Yang, a partner at Altimeter Capital, said that the company is also starting to unlock use cases for all that data, which is one reason Altimeter was attracted to H1. “The company saw incredible traction and growth with its first use case of helping pharma and life sciences identify key opinion leaders,” she told TechCrunch. The nature of the data the company has collected has started to shift. This year, however, the company has allowed physicians to start to “enhance” their own profiles. And, in the long-term, that user-generated data is one way the company might cement it’s place in the medical professional ecosystem. “Life science companies are hungry for data,” said Yang. “The H1 platform combines data from public, proprietary, and private sources – which enables H1 to uniquely unlock value. ”Over the course of this round, H1 has plans to sell to more pharma and life sciences companies by doubling down on go-to-market efforts.